Biocept

Biocept Treasury Stock

The Treasury Stock of Biocept (BIOCQ) as of Nov 20, 2026 is 307.30 M USD. In the previous year, Treasury Stock was 303.83 M USD — a change of 1.14% (higher).

Treasury Stock

307.30 MUSD

YoY

1.14%

Last updated:

Treasury Stock of Biocept is 2022 307.30 M USD. Treasury Stock of Biocept was 2021 303.83 M USD. It decreases by 1.14% higher compared to the previous year.

The Biocept Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2019
256.92 M USD
Jan 1, 2020
287.22 M USD
Jan 1, 2021
303.83 M USD
Jan 1, 2022
307.30 M USD
The Biocept Treasury Stock history
YEARTreasury StockYoY
307.30 MUSD+1.14%
303.83 MUSD+5.78%
287.22 MUSD+11.79%
256.92 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Stock analysis

What does Biocept do? Biocept, Inc. generates revenue through its oncology laboratory services, focusing on the detection of rare cells such as circulating tumor cells. The company markets its CNSide brand, which includes a suite of cellular and molecular technologies for central nervous system disease management. Its diagnostic assays, such as cell capture and enumeration, immunocytochemistry, FISH, and NGS, are commercialized for detecting various carcinomas and melanoma in blood and cerebrospinal fluid. Medical professionals and healthcare providers purchase these services to aid in patient diagnosis and treatment management. The CNSide product suite is designed for use in cerebrospinal fluid analysis, targeting solid tumor patients. Biocept's assays are specifically tailored for identifying rare tumor cells and cell-free tumor DNA, supporting clinical decision-making. The company's focus on solid tumors and CNS disease management positions it within the diagnostic laboratory services market, where healthcare institutions seek advanced tools for oncology care. Biocept's commercialized assays include cell capture, enumeration, immunocytochemistry, FISH, and NGS, all under the CNSide brand. These products are sold to medical professionals who require precise diagnostic tools for central nervous system disease management. The company's offerings are targeted at healthcare providers managing patients with solid tumors, particularly those requiring CSF analysis for disease monitoring and treatment planning. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Treasury Stock of Biocept is 307.30 M USD in 2022.

Treasury Stock of Biocept changed from 303.83 M USD to 307.30 M USD, representing a 1.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Biocept since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Biocept historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biocept

All Key Metrics — Biocept